Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating t… Read more
Alar Pharmaceuticals Inc. (6785) - Total Liabilities
Latest total liabilities as of June 2024: NT$69.15 Million TWD
Based on the latest financial reports, Alar Pharmaceuticals Inc. (6785) has total liabilities worth NT$69.15 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alar Pharmaceuticals Inc. - Total Liabilities Trend (2019–2023)
This chart illustrates how Alar Pharmaceuticals Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Alar Pharmaceuticals Inc. Competitors by Total Liabilities
The table below lists competitors of Alar Pharmaceuticals Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Giordano International Limited
PINK:GRDZF
|
USA | $1.65 Billion |
|
NanJing Sanchao Advanced Materials Co Ltd
SHE:300554
|
China | CN¥277.64 Million |
|
Grupo Clarin S.A.
BA:GCLA
|
Argentina | AR$215.00 Billion |
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
India | ₹30.75 Billion |
|
Marr S.p.A.
LSE:0NSS
|
UK | €926.41 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.22 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥581.46 Million |
|
Chongqing Yukaifa Co Ltd
SHE:000514
|
China | CN¥3.18 Billion |
Liability Composition Analysis (2019–2023)
This chart breaks down Alar Pharmaceuticals Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 39.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alar Pharmaceuticals Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alar Pharmaceuticals Inc. (2019–2023)
The table below shows the annual total liabilities of Alar Pharmaceuticals Inc. from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$76.09 Million | +839.02% |
| 2022-12-31 | NT$8.10 Million | +46.40% |
| 2021-12-31 | NT$5.54 Million | +3.03% |
| 2020-12-31 | NT$5.37 Million | +3604.83% |
| 2019-12-31 | NT$145.00K | -- |